4-(4-羟基-1-哌啶)-苯甲腈 | 79421-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(4-羟基-1-哌啶)-苯甲腈
• 英文名称: N-(4-cyanophenyl)-4-hydroxypiperidine
• 英文别名: 4-(4-hydroxypiperidin-1-yl)benzonitrile
• CAS: 79421-43-5
• 化学式: C₁₂H₁₄N₂O
• mdl: MFCD06656917
• 分子量: 202.256
• InChiKey: AIFMEOHBBANOOK-UHFFFAOYSA-N

物化性质

• 熔点：
  102-103 °C(Solv: benzene (71-43-2); hexane (110-54-3))
• 沸点：
  407.5±40.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  47.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(4-羟基-1-哌啶)-苯甲腈 在 吡啶 氢气 、 sodium hydride 、 二甲基亚砜 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 苯 为溶剂， 反应 26.5h， 生成 4-(4-(4-cyanobenzyl)piperidin-1-yl)benzonitrile
  参考文献：
  名称：

  Trypanocidal Activity of Conformationally Restricted Pentamidine Congeners

  摘要：

  A series of conformationally restricted congeners of pentamidine in which the flexible pentyl bridge of pentamidine was replaced by trans-1,2-bismethylenecyclopropyl, phenyl, pyridinyl, piperazinyl, homopiperazinyl, and piperidinyl groups were synthesized. The compounds were evaluated for trypanocidal activity in vitro and in vivo against one drug-sensitive and three drug-resistant trypanosome isolates. The DNA binding affinity of the compounds was also studied using calf thymus DNA and poly(dA-dT). The nature of the linker influenced the DNA binding affinity as well as the trypanocidal activity of the compounds. trans-1,2-Bis(4-amidinophenoxymethylene)cyclopropane (1) was over 25-fold more potent than pentamidine against the drug-resistant isolate KETRI 243As-10-3, albeit with comparable DNA binding affinity. NN'-Bis(4-amidinophenyl)homopiperazine (8) was the most potent trypanocide in vitro against all four trypanosome isolates studied, but N,N'-bis(4-amidinophenyl)piperazine (6) was the most effective agent in vivo against both drug-sensitive and drug-resistant trypanosomes.

  DOI：

  10.1021/jm020375q
• 作为产物：
  描述：

  4-哌啶-1-苯甲醛 以 乙醇 、 水 为溶剂， 以34%的产率得到4-(4-羟基-1-哌啶)-苯甲腈
  参考文献：
  名称：

  Floyd, Nicholas; Munyemana, Francois; Roberts, Stanley M., Journal of the Chemical Society. Perkin transactions I, 1993, # 8, p. 881 - 882

  摘要：

  DOI：

文献信息

• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• [EN] NEW OXADIAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'OXADIAZOLE
  申请人：ALMIRALL SA

  公开号：WO2011113578A1

  公开（公告）日：2011-09-22

  The present invention relates to an oxadiazole derivative of formula (I)1 or a pharmaceutically acceptable salt or N-oxide thereof: wherein, R1 represents a hydrogen atom, a C1-2 alkyl group or a C3-4 cycloalkyl-C1-2 alkyl group, both R2 and R3 represent a C1-2 alkyl group; Ra represents a hydrogen atom or a C1-2 alkyl group; Rb represents a hydrogen atom, a C1-2 alkyl group, a C3-4, cycloalkyl group, a carboxy group, a carbamoyl group or a -CF3 group; Rc represents a linear or branched C2.5 alkyl group substituted with one substituent selected from a hydroxy group, a triazolyl group and a -P(O)(OH)2 group; a -(CH2)(1-2)-C(O)OR' group; a -NR'R" group; a -(CH2)(1-2NR'R" group; a -(CH2)(1-2)-NHC(O)R" group; a -(CH2)(2-4)NH-(CH2)(1-3)-NR'R" group; or a -O-(CH2)(2-3)NR'R" group, wherein: R' represents a hydrogen atom or a C1-2 alkyl group, R" represents a hydrogen atom; a C5-6 cycloalkyl group substituted with a carboxy group; a 5- to 6-membered saturated heterocyclic ring containing one nitrogen atom and substituted with a carboxy(C1-2alkyl) group; or a C1-2 alkyl group optionally substituted by one or more substituents selected from halogen atoms, hydroxy groups, methyl groups, amino groups, carbamoyl groups and carboxy groups; or R' and R" together with the nitrogen atom to which they are attached form (a) a 4 to 6 membered saturated or unsaturated heterocyclic group, which contains, as heteroatom, one N atom and, optionally, one further N atom and which heterocyclic group is substituted with one or more substituents selected from a halogen atom, a hydroxy group, a methyl group, an oxy group and a carboxy group, or (b) a 5 membered heteroaryl group which contains, as heteroatom, one N atom and, optionally, one or more further N atoms and which heteroaryl group is optionally substituted with one substituent selected from an amino group and a carboxy group.

  本发明涉及式(I)1的噁二唑衍生物或其药用盐或N-氧化物：其中，R1表示氢原子，C1-2烷基或C3-4环烷基-C1-2烷基；R2和R3都表示C1-2烷基；Ra表示氢原子或C1-2烷基；Rb表示氢原子，C1-2烷基，C3-4环烷基，羧基，脒基或- CF3基；Rc表示用羟基，三唑基和-O-(OH)2基中选择的一个取代基取代的直链或支链C2.5烷基；-(CH2)(1-2)-C(O)OR'基；-NR'R"基；-( )(1-2)NR'R"基；-( )(1-2)-NHC(O)R"基；-( )(2-4)NH-( )(1-3)-NR'R"基；或-O-( )(2-3)NR'R"基，其中：R'表示氢原子或C1-2烷基，R"表示氢原子；用羧基取代的C5-6环烷基；含有一个氮原子并用羧基(C1-2烷基)基团取代的5至6元饱和杂环；或用卤素原子，羟基，甲基，氨基，脒基和羧基中选择的一个或多个取代基取代的C1-2烷基；或R'和R"与它们连接的氮原子一起形成(a)含有一个N原子和一个或多个N原子的4至6元饱和或非饱和杂环，该杂环被卤素原子，羟基，甲基，氧基和羧基中的一个或多个取代基取代，或(b)含有一个N原子和一个或多个N原子的5元杂芳基，该杂芳基可被氨基和羧基中的一个取代基取代。
• New oxadiazole derivatives
  申请人：Almirall, S.A.

  公开号：EP2366702A1

  公开（公告）日：2011-09-21

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: and its use in the treatment of diseases which are susceptible to improvement by sphingosine-1-phosphate (S1P1) receptor agonists.

  本发明涉及式(I)的化合物，或其药用可接受的盐或N-氧化物： 及其用于治疗可以通过鞘氨醇-1-磷酸(S1P1)受体激动剂改善的疾病。
• Anti-Inflammation Compounds
  申请人：No Zaesung

  公开号：US20140155387A1

  公开（公告）日：2014-06-05

  The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR 4 , C═O, C═S, OP(O)(O), P═O, CH 2 , or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C═O, O, S, CH 2 , or NR 5 ; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

  本发明涉及一种具有通式（I）的化合物，其中n为0、1、2或；m为0、1、2或3；o为0、1、2或3；W、X、Y和Z分别独立地选自CH、N或N-氧化物；A为NR4、C═O、C═S、OP(O)(O)、P═O、CH2，或从（a）、（b）、（c）、（d）、（e）、（f）、（g）组成的群体中选择的杂环基；V为C═O、O、S、 或NR5；以及其在治疗哮喘、COPD、感染后炎症、关节炎、动脉粥样硬化、疼痛和皮炎等炎症性疾病中的用途。
• Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203
  作者：Sunhee Kang、Young Mi Kim、Ryang Yeo Kim、Min Jung Seo、Zaesung No、Kiyean Nam、Sanghee Kim、Jaeseung Kim

  DOI：10.1016/j.ejmech.2016.09.082

  日期：2017.1

  modified by varying its side chain. In this study, we synthesized Q203 analogues with different side chains and studied their effects on anti-tubercular activity. Many analogues showed good potency against M. tuberculosis replicating in liquid broth culture medium (extracellular activity) regardless of chain length and conformational changes. However, a polar character in the side chain region was unfavorable

  6-氯-2-乙基-N-（4-（4-（4-（三氟甲氧基）苯基）哌啶-1-基）苄基）咪唑并[1,2- a ]吡啶-3-的抗结核活性羧酰胺（Q203）通过改变其侧链进行修饰。在这项研究中，我们合成了具有不同侧链的Q203类似物，并研究了它们对抗结核活性的影响。许多类似物对M显示出良好的效力。结核菌在液体肉汤培养基中复制（细胞外活性），而与链长和构象变化无关。但是，侧链区域的极性特征不利于抗结核活性。的类似物，25，28，35和36，对M表现出出色的活性。结核在巨噬细胞内部复制（细胞内活性），并具有较高的药物暴露水平和较长的半衰期，具有良好的药代动力学（PK）特性。